Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia
Article first published online: 8 MAR 2011
Copyright © 2011 American Neurological Association
Annals of Neurology
Volume 69, Issue 2, pages 303–311, February 2011
How to Cite
Lancaster, E., Huijbers, M. G. M., Bar, V., Boronat, A., Wong, A., Martinez-Hernandez, E., Wilson, C., Jacobs, D., Lai, M., Walker, R. W., Graus, F., Bataller, L., Illa, I., Markx, S., Strauss, K. A., Peles, E., Scherer, S. S. and Dalmau, J. (2011), Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol., 69: 303–311. doi: 10.1002/ana.22297
- Issue published online: 8 MAR 2011
- Article first published online: 8 MAR 2011
- Accepted manuscript online: 28 OCT 2010 07:32AM EST
- Manuscript Accepted: 1 OCT 2010
- Manuscript Revised: 17 SEP 2010
- Manuscript Received: 5 AUG 2010
To report clinical and immunological investigations of contactin-associated protein-like 2 (Caspr2), an autoantigen of encephalitis and peripheral nerve hyperexcitability (PNH) previously attributed to voltage-gated potassium channels (VGKC).
Clinical analysis was performed on patients with encephalitis, PNH, or both. Immunoprecipitation and mass spectrometry were used to identify the antigen and to develop an assay with Caspr2-expressing cells. Immunoabsorption with Caspr2 and comparative immunostaining of brain and peripheral nerve of wild-type and Caspr2-null mice were used to assess antibody specificity.
Using Caspr2-expressing cells, antibodies were identified in 8 patients but not in 140 patients with several types of autoimmune or viral encephalitis, PNH, or mutations of the Caspr2-encoding gene. Patients' antibodies reacted with brain and peripheral nerve in a pattern that colocalized with Caspr2. This reactivity was abrogated after immunoabsorption with Caspr2 and was absent in tissues from Caspr2-null mice. Of the 8 patients with Caspr2 antibodies, 7 had encephalopathy or seizures, 5 neuropathy or PNH, and 1 isolated PNH. Three patients also had myasthenia gravis, bulbar weakness, or symptoms that initially suggested motor neuron disease. None of the patients had active cancer; 7 responded to immunotherapy and were healthy or only mildly disabled at last follow-up (median, 8 months; range, 6–84 months).
Caspr2 is an autoantigen of encephalitis and PNH previously attributed to VGKC antibodies. The occurrence of other autoantibodies may result in a complex syndrome that at presentation could be mistaken for a motor neuron disorder. Recognition of this disorder is important, because it responds to immunotherapy. Ann Neurol 2011